Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00488566 | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers | PHASE1 | COMPLETED | 50 | — | — | May 31, 2007 | May 31, 2008 | Oct 26, 2017 | 2 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part 1 | OTHER | Single dose escalation |
| Part 2 | OTHER | Pharmacodynamic assessment |
| Name | Type | Description |
|---|---|---|
| GSK drug | DRUG | GSK drug |
| Placebo | OTHER | Placebo |
| Lamictal | OTHER | Positive control |
Part 1 Inclusion Criteria: * Healthy male subjects aged between 18 and 65 yrs and female (of non-child bearing potential) subjects aged between 18 and 50 years. Part 2 Inclusion Criteria: * right-handed healthy male subjects aged between 18 and 65 years. Parts 1 \& 2 Inclusion Criteria: * body ...